Eli Lilly announced that CVS Caremark will begin covering its obesity drug Foundayo starting June 1 and will resume coverage for Zepbound by October 1, making these treatments more accessible through major pharmacy benefit managers. Eligible patients with commercial insurance may pay as little as $25 per month, and Medicare Part D beneficiaries could pay $50 monthly via a special program. Foundayo is a once-daily oral pill, and Zepbound is a widely prescribed injectable, both FDA-approved for weight management. This expanded coverage aims to provide more Americans with effective obesity treatment options under their existing insurance plans.
Eli Lilly announced that CVS Caremark will add its GLP-1 medications, including the new pill Foundayo and injection Zepbound, to their formularies starting next week. This move could allow millions of Americans to access these drugs if their employer...
Eli Lilly continues to outperform revenue expectations and is expanding its drug pipeline through strategic acquisitions in infectious diseases and other areas. While new infectious disease treatments like amezosvatein show promise, significant reven...
Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss ...
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nord...
The Ebola epidemic in the Democratic Republic of the Congo has infected over 1,000 people and caused more than 220 deaths in less than two weeks, spreading to Uganda as well. The current outbreak involves the Bundibugyo strain, which lacks an approve...
